Bioatla Inc (BCAB) Stock Price, Quote & News

Company Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma o...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 0708

Fax: 858 558 0709

Website: www.bioatla.com

Address:

11085 Torreyana Road, San Diego, United States

shortkiller7 Dec. 5 at 2:43 AM

$BCAB 길을잃어버렸어요 리어카가보이네요 어디로가야하나요 드럽게머네

0 · Reply

Gator5326 Dec. 4 at 9:25 PM

$BCAB Major announcement today: FDA head Makary told STAT news that he is proposing that all all medical products should only need 1 pivotal trial for approval. Which means instead of a Ph2 and Ph3 it would only need one of them. Typically Ph2 has less participants so it's expected that those numbers will increase if Ph3 is skipped. Right now due to fast track designations about 66% of drugs are approved after a Ph2 anyway. TIMING: Policy people are expecting a lot of pushback here so it's not a sure thing - From STAT: The agency will publish a press release soon, a spokesperson later told us. Makary said the agency will also start updating policies to reflect the change, which could take three to six months. The change will take effect once the guidance is updated.

0 · Reply

Gator5326 Dec. 4 at 8:26 PM

$BCAB end of year only weeks away! “We remain on track for completing a partnership transaction by year end.” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla.

1 · Reply

Toro_of_Ga Dec. 4 at 6:52 PM

$BCAB “He that can have patience can have what he will.”

0 · Reply

pankooo Dec. 4 at 6:52 PM

$BCAB today 0.92 I hope.

0 · Reply

BioMan122 Dec. 4 at 5:41 PM

$BCAB price overvaluing financial difficulties. undrvaluing promisung data. at this pps level much mor upside than downside in my book. yes it can tank a bit but any average deal news will ruin all shorts

0 · Reply

BIOCARP Dec. 4 at 4:53 PM

$BCAB Rotate the triangulation, clear path up to $0.90. Then hit $1.20.

0 · Reply

BIOCARP Dec. 4 at 4:19 PM

$BCAB If anyone's interested in crypto, let my forum colleagues know. Check out $EUL.X A 15% incline. Just in case anyone's interested.

0 · Reply

BIOCARP Dec. 4 at 4:13 PM

$BCAB Come on, it's going to jump any minute now and go straight up without hesitation. This zone is already over. Or at $0.78 or $0 to $1.

0 · Reply

BiotechValues Dec. 4 at 4:10 PM

$BCAB obviously a lot of different potential partners out there (big or mid-cap), but maybe, just maybe (ChatGPT's prediction for mid-cap) $EXEL:

0 · Reply

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

Nov 13, 2025, 6:51 PM EST - 21 days ago

BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 21 days ago

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

$BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas$

Nov 7, 2025, 9:00 AM EST - 27 days ago

BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

Nov 5, 2025, 8:00 AM EST - 4 weeks ago

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

Oct 23, 2025, 8:00 AM EDT - 6 weeks ago

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

$BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025$

Oct 20, 2025, 8:00 AM EDT - 6 weeks ago

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Oct 3, 2025, 9:00 AM EDT - 2 months ago

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

Sep 8, 2025, 8:00 AM EDT - 3 months ago

BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA

Aug 9, 2025, 2:43 AM EDT - 4 months ago

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:23 PM EDT - 4 months ago

BioAtla (BCAB) Q2 Loss Narrows 27%

Aug 7, 2025, 4:05 PM EDT - 4 months ago

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 4, 2025, 8:00 AM EDT - 4 months ago

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 5 months ago

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

$BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress$

Jul 3, 2025, 8:00 AM EDT - 5 months ago

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Jun 2, 2025, 8:00 AM EDT - 6 months ago

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

May 6, 2025, 5:55 PM EDT - 7 months ago

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 7 months ago

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

Apr 30, 2025, 8:00 AM EDT - 7 months ago

BioAtla to Participate in the Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 7 months ago

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Apr 24, 2025, 8:00 AM EDT - 8 months ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Apr 23, 2025, 10:05 AM EDT - 8 months ago

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 27, 2025, 6:18 PM EDT - 9 months ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 5:05 PM EDT - 9 months ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 4:05 PM EDT - 9 months ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 20, 2025, 8:00 AM EDT - 9 months ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 19, 2025, 8:00 AM EDT - 9 months ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 4, 2025, 7:34 AM EST - 9 months ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dec 20, 2024, 9:00 AM EST - 1 year ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 16, 2024, 8:00 AM EST - 1 year ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Nov 9, 2024, 8:53 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Oct 8, 2024, 6:12 AM EDT - 1 year ago

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 7, 2024, 11:29 AM EDT - 1 year ago

BioAtla: Numerous Catalysts Coming In Q4

Oct 4, 2024, 9:05 AM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 1, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Sep 23, 2024, 7:30 AM EDT - 1 year ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Aug 11, 2024, 1:32 AM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 5:39 PM EDT - 1 year ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

May 29, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 23, 2024, 5:05 PM EDT - 1 year ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 8:35 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 8, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 6, 2024, 8:00 AM EDT - 1 year ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

May 2, 2024, 10:03 AM EDT - 1 year ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

Apr 24, 2024, 4:35 PM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Mar 26, 2024, 7:21 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 4:01 PM EDT - 1 year ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

shortkiller7 Dec. 5 at 2:43 AM

$BCAB 길을잃어버렸어요 리어카가보이네요 어디로가야하나요 드럽게머네

0 · Reply

Gator5326 Dec. 4 at 9:25 PM

0 · Reply

Gator5326 Dec. 4 at 8:26 PM

1 · Reply

Toro_of_Ga Dec. 4 at 6:52 PM

$BCAB “He that can have patience can have what he will.”

0 · Reply

pankooo Dec. 4 at 6:52 PM

$BCAB today 0.92 I hope.

0 · Reply

BioMan122 Dec. 4 at 5:41 PM

0 · Reply

BIOCARP Dec. 4 at 4:53 PM

$BCAB Rotate the triangulation, clear path up to $0.90. Then hit $1.20.

0 · Reply

BIOCARP Dec. 4 at 4:19 PM

$BCAB If anyone's interested in crypto, let my forum colleagues know. Check out $EUL.X A 15% incline. Just in case anyone's interested.

0 · Reply

BIOCARP Dec. 4 at 4:13 PM

$BCAB Come on, it's going to jump any minute now and go straight up without hesitation. This zone is already over. Or at $0.78 or $0 to $1.

0 · Reply

BiotechValues Dec. 4 at 4:10 PM

$BCAB obviously a lot of different potential partners out there (big or mid-cap), but maybe, just maybe (ChatGPT's prediction for mid-cap) $EXEL:

0 · Reply

BIOCARP Dec. 4 at 3:03 PM

$BCAB Don't forget it!!!

0 · Reply

BIOCARP Dec. 4 at 3:02 PM

$BCAB

0 · Reply

shortkiller7 Dec. 4 at 1:23 PM

$BCAB 가라나이다센라스마에바쿼사티아콤자보차한카번타맞파아하봐라

1 · Reply

shortkiller7 Dec. 4 at 11:00 AM

$BCAB who is next guy at bioatla like Martin Shkreli at short position at $CAPR ? 뒤지고 싶으면 공매도 쳐라 신나게

0 · Reply

shortkiller7 Dec. 4 at 8:29 AM

$BCAB Short sellers hold 50% of the daily volume, but they can't lower the price any more. Because someone is buying all of them down below. Now we're going to see a short cover with LO news. Short sellers currently hold close to 10% of the stock.

0 · Reply

BIOCARP Dec. 4 at 8:26 AM

$BCAB Let's not forget that our trading range, and where it will likely move in the coming days until the news triggers a surge, is the rectangle. Complete confidence. We're seeing our trading range increase daily.

1 · Reply

BIOCARP Dec. 4 at 8:24 AM

$BCAB Breaking through $0.86 today, it's headed higher. We'll see. Yesterday they tried to control it at the last minute by selling a few thousand shares. They know it's going to skyrocket and are trying to control it to buy back in. They'll fail.

1 · Reply

onemillion2012 Dec. 4 at 5:44 AM

$BCAB Boom Boom Boom.

1 · Reply

shortkiller7 Dec. 3 at 11:52 PM

$BCAB Hey short sellers, if you don't want to get in trouble like $CAPR, you better pay it back quickly

0 · Reply

squiggleburp Dec. 3 at 8:54 PM

$BCAB shoot, I’ll play, why not.

1 · Reply

Dpock23 Dec. 3 at 8:51 PM

$BCAB

0 · Reply

BIOCARP Dec. 3 at 8:21 PM

$BCAB Clear bounce at the lower end of the channel. Bullish engulfing pattern formed. We're heading towards the upper end of the channel. Clear path to $1.22. It's clear that more and more people want to be in. Then it goes up in pre-market trading, and those who aren't in will miss out.

1 · Reply

Market Cap	45.82M
Revenue (ttm)	11.00M
Net Income (ttm)	-69.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-634.36%
Debt to Equity Ratio	0.00

Volume	875,000
Avg Vol	1,554,106
Day's Range	N/A - N/A
Shares Out	58.79M
Stochastic %K	21%
Beta	1.01
Analysts	Sell
Price Target	$10.00